OpenEvidence - Official AI Medical Knowledge Platform of the United States - 2026

OpenEvidence is an American AI-powered clinical decision support (CDS) platform, positioned as "America's Official Medical Knowledge Platform." It provides verified healthcare professionals with AI-synthesized answers to clinical questions, grounded exclusively in peer-reviewed medical literature from leading global publishers, including NEJM, JAMA, NCCN, Cochrane, and Wiley.

As of 2026, OpenEvidence is the fastest-growing clinical AI platform in U.S. history: it is used by over 757,000 verified physicians across 10,000+ hospitals and medical centers, representing more than 40% of practicing U.S. doctors. The company reached a valuation of $12 billion after its $250 million Series D round in January 2026.

History and Founders

OpenEvidence was founded by Harvard and MIT-trained researchers and launched through the Mayo Clinic Platform Accelerate program, which provided initial validation from one of the United States' leading medical institutions.

Since launch, the platform has demonstrated exponential user growth. By early 2026, over 757,000 verified physicians had registered, representing more than 40% of all practicing U.S. doctors. The platform is in use at over 10,000 hospitals and outpatient centers nationwide.

Funding and Valuation

In January 2026, OpenEvidence closed a $250 million Series D funding round, valuing the company at $12 billion. The platform remains free for verified healthcare professionals. Monetization is achieved through pharmaceutical advertising with a cost-per-mille (CPM) ranging from $70 to $150+.

License fees from partnerships with leading medical publishers may also contribute to revenue, although specific financial terms are not disclosed.

Partnerships

OpenEvidence has entered into strategic content licensing agreements with the world's leading medical publishers and organizations:

NEJM Group (The New England Journal of Medicine) — Official AI Partner (February 2025)
JAMA Network (Journal of the American Medical Association) — Official AI Partner (2025)
National Comprehensive Cancer Network (NCCN) — Official AI Collaboration (November 2025)
Wiley — Strategic Partnership (March 2026)
Cochrane Library — License Agreement (2025)
American Medical Association (AMA) — Partnership (2025)
American College of Cardiology (ACC) — Partnership (2025)
American Academy of Family Physicians (AAFP) — Partnership (2025)

In July 2026, OpenEvidence announced a partnership with the Los Angeles County Department of Public Health to deliver localized public health guidance to physicians.

Key Features

Quick Consult

Rapid answer mode for clinical questions. The physician enters a natural language query, and the AI model generates a response in seconds, based on peer-reviewed sources with direct citations and links to original articles.

Deep Consult

Multi-source literature synthesis mode for complex clinical cases. The AI system analyzes numerous publications, synthesizes data, and presents a comprehensive analysis with full source attribution.

Visits (Real-Time Medical Intelligence)

Launched in August 2025. "Visits" provides real-time AI support during patient encounters. The system automatically analyzes the conversation between doctor and patient, offers relevant clinical recommendations, and can perform ambient clinical documentation.

AI-Integrated Doctor Dialer

Released broadly in February 2026. An integrated telemedicine system with AI support, providing secure audio and video communication between physician and patient. Features include messaging, faxing, and voicemail, with the AI model remaining active to deliver real-time clinical recommendations.

Inline Journal Citation

Every AI-generated response includes direct source citations with journal name, authors, publication year, and DOI. Users can navigate to the full original article with a single click.

Security and Compliance

OpenEvidence prioritizes data protection and regulatory compliance:

HIPAA Compliance — The platform fully complies with the U.S. Health Insurance Portability and Accountability Act, including the Privacy, Security, and Breach Notification Rules.
SOC 2 Type II Certification — Independent audit verification that security controls are not only properly designed but have been operating effectively over an extended period.
Encryption — All data is encrypted in transit and at rest using industry-standard encryption protocols.
Infrastructure — The platform is hosted on secure cloud servers with multi-layered access controls.
Privacy Policy — OpenEvidence states that it does not share user questions or conversations with third parties, does not train AI models on protected health information, and does not use patient data for model training.

Distribution Model and Pricing

OpenEvidence is free for all verified healthcare professionals, including physicians, residents, and medical students. Verification is performed through license registries such as NPI and DEA. The platform charges no fees and requires no subscription from clinicians.

Revenue is generated through targeted pharmaceutical advertising displayed exclusively to verified medical professionals. Advertising CPM rates range from $70 to $150+ per thousand impressions.

Impact on Medical Practice

According to a survey conducted on Sermo (an international physician community), 60% of doctors had heard of OpenEvidence, while 37% were unfamiliar with the platform. 20% of physicians expressed full support for AI in clinical decision-making, 54% were cautiously open, and 21% were skeptical.

Physician reviews describe the platform as "like having a top-tier research assistant," "a massive time-saver," and "a tool that helps us be more efficient, precise, and stay updated."

In the scientific literature (NIH PubMed Central), OpenEvidence is described as "the superior option compared to ChatGPT" for medical tasks due to its focus on accuracy, authority, and source currency.

Key Timeline

2024 — Platform launched through Mayo Clinic Platform Accelerate
February 19, 2025 — NEJM Group content agreement signed
August 21, 2025 — "Visits" feature launched (real-time AI visit support)
November 5, 2025 — NCCN collaboration announced
2025 — Agreements signed with JAMA, Cochrane, AMA, ACC, AAFP
January 2026 — $250M Series D round; company valued at $12 billion
February 25, 2026 — AI-Integrated Doctor Dialer broadly released
March 3, 2026 — Wiley partnership announced
July 23, 2026 — Los Angeles County Department of Public Health partnership
July 25, 2026 — Privacy Policy updated
2026 — SOC 2 Type II certification achieved

Criticism and Limitations

Despite widespread adoption, the platform faces several challenges:

Dependence on pharmaceutical funding — The advertising-based monetization model may raise concerns about conflicts of interest, though the platform states editorial content is fully independent.
Verification requirement — The platform is unavailable to the general public and patients, limiting its use outside clinical settings.
Language barrier — OpenEvidence is primarily English-language and oriented toward the U.S. healthcare system.
Competition with established resources — OpenEvidence competes with entrenched platforms such as UpToDate (Wolters Kluwer), DynaMed (EBSCO), and ClinicalKey (Elsevier), which have longer track records.

Technology

The platform combines large language models (LLMs) with retrieval-augmented generation (RAG) technology, allowing the AI system to deliver responses based exclusively on verified medical content from licensed sources, minimizing the risk of hallucination common to general-purpose AI chatbots.

OpenEvidence has also deployed specialized medical AI models trained on a corpus of peer-reviewed medical literature to ensure maximum accuracy in clinical scenarios.

Summary

OpenEvidence is an American AI clinical decision support platform that provides verified physicians with free access to AI-synthesized answers to clinical questions, grounded exclusively in peer-reviewed medical literature. The platform is the official AI partner of NEJM, JAMA, and NCCN, and has agreements with Wiley, Cochrane, and other leading medical publishers. As of 2026, OpenEvidence is used by over 757,000 physicians (40%+ of practicing U.S. doctors) and is valued at $12 billion. The platform is free for clinicians and funded through pharmaceutical advertising. OpenEvidence is HIPAA-compliant and holds SOC 2 Type II certification.

References

×